Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Abstract #： 306-OR Presentation Form: Oral presentation Time: 2025 June 23, 14:15 PM – 14:30 PM（CST） Presenter: Dr. Lei Qian, Innovent Biologics Title: A novel antibody-peptide conjugate targeting ...

Novo Nordisk (NYSE: NVO) announced Thursday it will initiate Phase 3 trials for its experimental weight-loss drug amycretin in both injection and oral forms during the first quarter of 2026. The ...

Amycretin, the Danish drugmaker’s next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...